Jefferies Financial Group Inc. Purchases 200,000 Shares of Compass Pathways PLC Sponsored ADR $CMPS

Jefferies Financial Group Inc. boosted its position in Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) by 14.5% during the fourth quarter, Holdings Channel.com reports. The fund owned 1,576,905 shares of the company’s stock after acquiring an additional 200,000 shares during the period. Jefferies Financial Group Inc.’s holdings in Compass Pathways were worth $10,881,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in the company. Eagle Health Investments LP grew its holdings in Compass Pathways by 62.4% in the 4th quarter. Eagle Health Investments LP now owns 1,519,388 shares of the company’s stock worth $10,484,000 after acquiring an additional 583,938 shares during the last quarter. HighTower Advisors LLC grew its holdings in Compass Pathways by 172.8% in the 4th quarter. HighTower Advisors LLC now owns 31,491 shares of the company’s stock worth $217,000 after acquiring an additional 19,949 shares during the last quarter. U.S. Capital Wealth Advisors LLC bought a new stake in Compass Pathways in the 4th quarter worth $104,000. Hennion & Walsh Asset Management Inc. grew its holdings in Compass Pathways by 169.0% in the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 424,800 shares of the company’s stock worth $2,931,000 after acquiring an additional 266,908 shares during the last quarter. Finally, Advisory Services Network LLC bought a new stake in Compass Pathways in the 3rd quarter worth $41,000. Institutional investors own 46.19% of the company’s stock.

Compass Pathways Stock Performance

NASDAQ:CMPS opened at $11.81 on Monday. The company has a 50-day moving average price of $7.63 and a 200-day moving average price of $6.91. Compass Pathways PLC Sponsored ADR has a 12 month low of $2.25 and a 12 month high of $12.24. The company has a current ratio of 3.32, a quick ratio of 3.32 and a debt-to-equity ratio of 0.15. The stock has a market cap of $1.59 billion, a price-to-earnings ratio of -3.75 and a beta of 2.39.

Compass Pathways (NASDAQ:CMPS) last posted its earnings results on Wednesday, May 13th. The company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.45) by $0.15. Equities analysts predict that Compass Pathways PLC Sponsored ADR will post -1.24 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on CMPS shares. Royal Bank Of Canada raised their price target on shares of Compass Pathways from $21.00 to $22.00 and gave the stock an “outperform” rating in a report on Thursday, May 14th. Jefferies Financial Group raised shares of Compass Pathways to a “strong-buy” rating in a report on Tuesday, May 5th. BTIG Research reaffirmed a “buy” rating and issued a $14.00 target price on shares of Compass Pathways in a research report on Wednesday, May 13th. Compass Point set a $15.00 target price on shares of Compass Pathways in a research report on Thursday, February 12th. Finally, Maxim Group raised their target price on shares of Compass Pathways from $12.00 to $20.00 and gave the stock a “buy” rating in a research report on Friday, May 15th. Two equities research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $20.58.

Compass Pathways Profile

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.